PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Forth allows users to track their wellbeing to see what impact their lifestyle is having on their health. It allows users to maximise their performance during athletics, keep track of their inner health and focus on things they may need to work on for greater overall wellbeing.
days to go:
Expired
investment:
£165,760
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.
days to go:
Expired
investment:
£30,564
Castledene Sales and Lettings is a group of property companies based in the North East of England. They will be opening a new branch for investors to invest in which will be based in Spennymoor. Castledene offer both sales and lettings packages aswell as selling investment properties and providing their Rent-to-Own scheme.
days to go:
Expired
investment:
£60,000
Elite Training Experience (ETE) aims to become the de facto provider of warm weather triathlon training camps, not just to the UK's 140,000 triathletes but to the estimated 2,000,000 triathletes around the world.
days to go:
Expired
investment:
£139,470
The LetPal solution for private landlords is a full suite of competitively priced on-line services, from which landlords can select and pay for only those they require.
days to go:
Expired
investment:
£70,000
A new form of electric transport in the bike industry with the use of an affordable and simple conversion kit. Swytch have developed a kinetically rechargeable add-on for existing bikes to convert them into eBikes for a range of up to 50 miles. Funding will result in additional units being manufactured and sold at a 70% margin. The products are available online and currently via 20 independent bike dealers, with over 100 more waiting on stock.
days to go:
Expired
investment:
£349,356
Train My Athlete is a mobile application that puts your athlete at the centre of world class care. Train My Athlete enables athletic medical teams to deliver elite training, rehab, coaching, diet and nutrition plans directly to the athletes phone or tablet.
days to go:
Expired
investment:
£11,890
